patients treated with the drug for a number of indications. They reported a 29 percent arrhythmia recurrence rate and a 19 percent incidence of severe side effects in the first year of therapy. The reasons for these disparate results can only be surmised. Inadequate data collection in the foreign experience could be invoked but seems implausible given the uniformity ofthe experience. Some unique susceptibility of American patients would seem a highly contrived explanation. A basic difference in how the drug has been used appears most likely. In fact, a careful review of studies to date indicates a significant difference in the dose of amiodarone employed. American investigators have consistently used higher doses of the drug long-term. For example, the average daily dose in the report of Mason et al'2 was 443 + 330 mg compared with 200 to 300 mg in the European literature.
whom 57 had manifested either ventricular tachycardia or fibrillation. All were loaded either intravenously (17) or orally, and maintained on an oral dose of 200 to 600 mg/day (mean daily dose 317 ± 114 mg) and followed for 4 to 58 months (22 ± 11) . Results indicated that amiodarone was a safe and effective antiarrhythmic drug when used in lower doses.
The purpose of this study was to determine in a prospective fashion whether amiodarone is a safe and effective drug when administered in low doses.
METHODS
Patients referred to the Cardiac Arrhythmia Service at the Medical College of Pennsylvania were eligible for inclusion into the study. The protocol and consent form had been reviewed and approved by the Committee for the Protection of Human Subjects of the Medical College. The study entry criterion was a serious cardiac arrhythmia which had not responded to one or more conventional antiarrhythmic drugs. This was defined as persistent or recurrent spontaneous or induced supraventricular or ventricular tachyarrhythmia which, in the opinion ofthe patient's physician, constituted a significant impediment to the patient's health or well-being. Patients were excluded if the arrhythmia was deemed by the investigators to be not serious (not causing hemodynamic compromise or loss of consciousness), or if careful, long-term follow-up was precluded for any reason including poor general health or unreliability.
Preliminary cardiac testing was performed in all cases, and included ambulatory monitoring, and/or invasive electrophysiologic testing (using previously described techniques) to define the nature and extent ofthe cardiac arrhythmia. A battery ofbaseline laboratory testing was also obtained in each case and consisted ofa hematologic profile, serum chemistries, hepatic, renal and thyroid function tests, antinuclear antibody test, chest x-ray, and slit-lamp eye examination. Patients then underwent either intravenous or oral loading. Intravenous loading consisted of 5 mg/kg infused over 30 minutes followed by a constant infusion of 900 mg/day for two days. Oral dosing was begun concomitantly with 800 mg for three days followed by 400 mg for three days. The oral program was decremental starting at 1,200 mg/day, and decreased by 400 mg every three days until a maintenance dose of 400 mg was achieved. Dose adjustments were permitted during the loading program if the QT interval did not show significant alteration (at least a 10 percent increase was expected by the end ofthe loading period). This loading program was used as a guideline but allowed physician discretion in the choice of the next daily dose.
At the end of the seven to ten day loading period and administration of an average loading dose of 7.2 g, repeat cardiac testing was carried out. Criteria for efficacy included abolition of nonsustained ventricular tachycardia on monitoring and/or a significant slowing or noninducibility of a formerly inducible arrhythrnia in the electrophysiology laboratory. Slowing of arrhythmia was considered significant if the cycle length increased to greater than 400 ms and was well tolerated hemodynamically while the patient was supine. If the arrhythmia was unaltered by amiodarone, an alternative treatment was selected. Those patients in whom a salutary response was obtained remained on the drug long-term. Patients with a partial response also remained on the drug, used either alone or in combination with another partially effective antiarrhythmic agent. Partial response was defined as rate slowing but poor hemodynamic tolerance or >75 percent but <100 percent abolition ofnonsustained VT salvoes. The usual daily dose used in the maintenance phase was the lowest that maintained antiarrhythmic efficacy and generally was 300 to 400 mg in patients with ventricular arrhythmia and 200 mg in patients with supraventricular arrhythmia. All patients were followed after hospital discharge by the investigators in conjunction with the private referring physicians. Patients were seen every three to six months, and an ECG was obtained at every visit. Twice annual testing consisted of a repeat of the laboratory testing obtained at baseline, together with a 24-hour ambulatory monitoring. Dose adjustments were made by the investigators and consisted only of down titration in those patients who had been discharged on a dose higher than the recommended maintenance amount because of a persistently foreshortened QT interval. Dose titration was not employed to treat tolerable or treatable side-effects. The drug was withdrawn if the patient developed intolerable side-effects or had a documented arrhythmia recurrence deemed serious by the investigator and/or private physician, or if a very rapid tachycardia remained inducible in the electrophysiology laboratory after the period of intravenous or oral loading.
RESULTS
A total of 68 patients participated in the study, including 60 men and eight women with a mean age of 59 years. Fifty-seven patients had presented with hemodynamically significant VT Poorly Tolerated 0 testing was carried out in 58 patients both before and after amiodarone loading, and in the other ten, drug efficacy was gauged by the results of noninvasive testing. Patients studied noninvasively had greater than ten episodes of atrial fibrillation, greater than two episodes of supraventricular tachycardia, or >50 salvoes of nonsustained VT on ambulatory monitoring on each of two baseline 24-hour ambulatory monitorings. The average daily dose of amiodarone was 317 ± 114 mg for the total group.
Patients were followed for four to 58 months (22 ± 11). Results of therapy are shown in Figure 1 . Of the 11 patients with atrial flutter or fibrillation, eight (73 percent) had no recurrences including five who were treated with amiodarone alone and three who required another antiarrhythmic in combination. Of these eight, five had been studied invasively. One had been noninducible, while four had a slower tachycardia initiated (increase in cycle length of at least 100 ms in all cases) while on their discharge program. The other three patients were not studied invasively but had shown a >90 percent reduction in spontaneous arrhythmia frequency on ambulatory monitoring. There were three recurrences of supraventricular tachycardia, all well tolerated. Two of the three recurreinces were heralded by the repeated provocation of a slower version of the clinical arrhythmia in the laboratory, while in one, a slower supraventricular arrhythmia was repeatedly observed on ambulatory monitoring. Of the 57 patients with VT/VF, 44 (77 percent) remained arrhythmia-free during the period of follow-up, including 11 who were treated with amiodarone in combination with another antiarrhythmic drug. Notably, only eight of these patients were rendered completely noninducible, while in the other 32 tachycardia was made significantly slower. Amiodarone failed in 13 patients, including five who were tested in the electrophysiology laboratory and were deemed failures because their same rapid tachycardia could be easily induced. Eight patients suffered a spontaneous recurrence of their ventricular arrhythmia, of whom six died (one receiving combination therapy; one had the drug stopped by the private physician two months earlier). The two who survived their recurrence were successfully converted to an alternative investigational antiarrhythmic program. Six of the eight patients who suffered a recurrence had electrophysiologic testing. The rate of the recurrent arrhythmia was accurately predicted in four of these six; that is, a slower VT was induced in the two survivors, and a faster VT was induced in two of the four nonsurvivors. Two of the patients who died were not studied, but their monitoring continued to show runs ofnonsustained ventricular tachycardia.
Fifty-nine of the 68 patients had at least one side effect with amiodarone therapy. Adverse effects are Table 1 and are divided into the following three categories: nonserious, serious but not precluding drug continuation, and serious for which the drug was discontinued. A total of 100 adverse effects were noted. Eighty-eight (88 percent) of these were nonserious, and included corneal microdeposits, transaminase level elevation, sun sensitivity dermatitis, and a positive antinuclear antibody test. Twelve (12 percent) of the complications were serious but in only four cases was drug withdrawal required. Two ofthe cases of pulmonary fibrosis led directly to the patients' deaths from superinfection.
Overall, 11 patients died during the study period, including six who died suddenly, two whose deaths were not sudden but cardiac related, and three noncardiac deaths. Another ten patients were withdrawn for side-effects or for drug inefficiency demonstrated by a nonlethal recurrence or inducible arrhythmia in the electrophysiology laboratory. Figure 2 is an illustration ofwhen drug discontinuation occurred in the course of treatment. Six of the deaths (two sudden) and all of the laboratory failures occurred in the first two months of therapy. One of the patients who failed testing and received an automatic implantable defibrillator remained on the drug and died later of a noncardiac cause. The remaining cases of drug withdrawal were scattered throughout the follow-up period, occurring as late as 52 months after the initiation of therapy. 
DISCUSSION
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MTIIA remarkable efficacy rate together with good tolerance, and it was heralded as a "nearly ideal antiarrhythmic agent," effective for a variety of cardiac arrhythmias." The initial American experience was somewhat disappointing. When used in higher doses and subjected to the rigors of invasive electrophysiologic testing, the drug appeared to have a substantially higher rate of toxicity and more modest efficacy.'0"418 These differing results might be explainable on the basis ofa number of factors. Because of important regulatory issues, American investigators used the drug in patients with more malignant arrhythmia. These patients, who also tend to have more severe heart disease, might also be more susceptible to side-effects that would limit treatment. It could also be argued that, since the drug was investigational, closer clinical surveillance was carried out in the United States, and thus, more cases of drug toxicity were uncovered. However, it would appear even more plausible that the important difference was dose. Investigators outside of the United States consistently used doses in the range of200 mg daily, while American investigators have used much higher doses. For example, Waxman et al,'4 Greene et al,'5 and Rakita and Sobol'6 used maintenance doses of 400 to 800 mg/day, 600 mg/day, and 500 mg/day, respectively. Conversely, Harris et al,'9 in a retrospective study, used smaller doses (mean 360 mg/day) and reported a much lower incidence ofside-effects, including pulmonary fibrosis, serious enough to warrant drug withdrawal. Since a general relationship between dose and toxicity had been constructed, we concluded that use of lower doses might be safer but that the key element was whether lower doses would continue to yield a satisfactory clinical response. We therefore embarked on a prospective study to examine the safety and efficacy of an amiodarone regimen in which a concerted effort was made to use the lowest possible dose of the drug in the maintenance phase. The patient population studied, their arrhythmia treatment history, and their general medical condition were all similar to the profiles of patients who have received the drug in United States studies. Using an aggressive loading regimen, which in some cases included intravenous administration, standard invasive and noninvasive techniques of drug evaluation, and close clinical follow-up, we had an appreciable efficacy rate, defined by long arrhythmia-free intervals. As noted by other investigators, a beneficial effect of the drug could be defined in a number of ways. 1015,17,20 24 Reduction in the amount of ambient arrhythmia in those patients who had only noninvasive testing appeared to auger well. Although rendering the arrhythmia noninducible in the electrophysiology laboratory was a very useful endpoint, it happened rarely. Tachycardia slowing was much more common and usually indicated that the arrhythmia would not recur, but that if it did, the patient would tolerate it.
Only two patients had a relatively well-tolerated arrhythmia provoked in the laboratory and subsequently had a sudden death. This occurred despite the fact that downward dose titration was carried out in every patient after hospital discharge.
Many ofour patients experienced nonseriouis, and in most cases, only annoying side-effects. Corneal microdeposits, transaminase level elevation, and sun sensitivity were ubiquitous complications of therapy, but none ofthese evolved into more important toxicity. For example, none of our patients developed a blue skin pigmentation, perhaps because we were alerted to this possibility and aggressively counseled them to use sun screens, or specifically because we used a lower dose. More serious complications were much less common, and in most cases. did not lead to withdrawal of the drug. In most cases, the patients responded to institution of appropriate medical therapy, suich as thyroid replacement, and amiodarone could be continued. The complication that did cause discontinuation of the drug was pulmonary fibrosis of which we had three cases. Despite immediate cessation of the drug, two of our patients died as a direct result. In both cases, the patients had had a normal interim chest x-ray film (in one, performed only two weeks before) and the onset of toxicity was fulminant.
A particularly intriguing finding was the time at which complications developed. Since dosing was uniform, the time at which side-effects developed in our study is directly proportional to the cumulative dose of drug. Some 
